Multiple Endocrine Neoplasia Type 1 with Multiple Leiomyomas Linked to a Novel Mutation in the MEN1 Gene

Heekyoung Choi,1 Sehyun Kim,1 Jae-Hoon Moon,1 Yoon Hee Lee,2 Yumie Rhee,1,3 Eun Seok Kang,1,3 Chul Woo Ahn,1,3 Bong Soo Cha,1,3 Eun Jig Lee,1,3 Kyung Rae Kim,1,3 Hyun Chul Lee,1,3 Seon Yong Jeong,4 Hyun Ju Kim,4 and Sung-Kil Lim1,3

Departments of 1Internal Medicine and 2Pathology, 3Endocrine Research Institute, Yonsei University College of Medicine, Seoul; 4Department of Medical Genetics, Ajou University School of Medicine, Suwon, Korea.

INTRODUCTION

Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominantly inherited syndrome. MEN1 is characterized by the presence of functioning and nonfunctioning tumors or hyperplasia of the pituitary gland, parathyroid glands, and pancreatic islet cells. In addition, MEN1 carriers can have adrenal or thyroid tumors and non-endocrine tumors, such as lipomas, angiofibromas, and leiomyomas. Although leiomyoma is not a major component of MEN1, it is thought to occur more frequently than expected. However, there has been no report of a case of MEN1 with leiomyoma in Korea so far. This report describes a patient with multiple leiomyomas in MEN1. A 50-year-old woman was referred for further evaluation of elevated calcium levels and osteoporosis. Biochemical abnormalities included hypercalcemia with elevated parathyroid hormone. There was hyperprolactinemia with pituitary microadenoma in sella MRI. An abdominal MRI demonstrated adrenal nodules and leiomyomas in the bladder and uterus. Endoscopic ultrasonography demonstrated esophageal leiomyoma and pancreatic islet cell tumor. A subtotal parathyroidectomy with thymectomy was performed. Sequencing of the MEN1 gene in this patient revealed a novel missense mutation (D350V, exon 7). This is the first case of MEN1 accompanied with multiple leiomyomas, parathyroid adenoma, pituitary adenoma, pancreatic tumor, and adrenal tumor.

Key Words: Leiomyoma, multiple endocrine neoplasia type 1

CASE REPORT

A 50-year-old female presented with chronic fatigue. She was diagnosed with osteoporosis five years prior and was taking alendronate. Hypercalcemia was diagnosed two years following the osteoporosis diagnosis, and the patient visited the hospital for a comprehensive check-up. The patient did not have any history of diabetes,
hypertension, tuberculosis, or hepatitis. She was the first daughter of two sons and two daughters. Concurrently, her 81-year-old mother, who was bedridden for unknown reasons, was also undergoing tests for hypercalcemia, and was subsequently diagnosed with multiple parathyroid adenomas and pancreatic tumors, based on the test results. Her father had a history of sudden death by an acute cardiac event.

In the neck examination, the thyroid was not enlarged, and palpable tumors were absent. Heart and lung sounds were normal, and no abnormalities were detected in the abdomen, all extremities, or neurological tests. The axillary hair and the pubic hair were normal, hirsutism was absent, and galactorrhea was not observed.

In blood electrolyte tests, sodium was 144 mmol/L, potassium was 4.0 mmol/L, chloride was 107 mmol/L, blood calcium was 12.6 mg/mL, ionized calcium was 5.4 mg/dL, and inorganic phosphate was 3.3 mg/dL. In general biochemical tests, fasting blood glucose was 93 mg/dL, blood urea nitrogen was 8.9 mg/dL, blood urea nitrogen was 8.9 mg/dL, creatinine was 0.8 mg/dL, and the hepatic function test was normal. Her 24-hour urinary calcium excretion was 326 mg/day, the amount of phosphate excretion was 460 mg/day, and the creatinine clearance rate was 64 mL/min. Thyroid hormone tests were within normal range, and intact-PTH was increased to 99.8 pg/mL. Prolactin was also mildly increased to 27.63 ng/mL. Plasma insulin was 9.2 uIU/mL (4.2 - 48), gastrin was 21 pg/mL (0 - 90), glucagon was 40 pg/mL (40 - 130), pancreatic polypeptide was 79 pmol/L (<100), and vasoactive intestinal polypeptide was 32 pg/mL (<100). In dual X-ray absorptiometry (DXA), the T score of the femur was decreased to -2.0, confirming the osteopenia finding.

In the neck ultrasound, in the posterior area of the left thyroid, a tumor suspected to be a parathyroid adenoma 10 mm in size was detected, and in the parathyroid scan, uptake was detected in two glands (Fig. 1). In the neck computed tomography (CT), parathyroid tumors, 10 mm in the left side and 8 mm in the right side, were detected. In the chest CT, abnormal findings in the lung and the mediastinum were not detected. On the brain magnetic resonance imaging (MRI), a tumor 7 mm in size in the pituitary was detected (Fig. 2). On the abdominal MRI, a 2.3 cm left adrenal tumor and a pancreatic tumor were observed, and a 7 cm uterine myoma and a bladder wall myoma were detected (Fig. 3). Esophagogastro-duodenoscopy (EGD) and endoscopic ultrasonography (EUS) revealed an esophageal leiomyoma 20 mm in size in the area 20 cm away from the incisor, and in the pancreatic head, a tumor 6 mm in size was detected (Fig. 4). In general positron emission tomography (PET), increased fluorodeoxyglucose (FDG) uptake in the
pituitary was seen. Nonetheless, the increase of the uptake by other lesions was not detected, and thus indicated the benign nature of the multiple tumors.

From the peripheral blood of the patient and her mother, genomic DNA was extracted, and sequencing of the MEN1 gene was performed. Sequencing analysis revealed a transition of GAG to GTG at codon 350 of exon 7, causing an amino acid change from aspartic acid to valine, D350V (Fig. 5).

Because of the detection of double parathyroid adenoma, pituitary adenoma, pancreatic tumor, and adrenal cortical tumor, as well as accompanying multiple leiomyomas in the bladder, the uterus, and the esophagus, MEN1 was diagnosed. For parathyroid adenoma, a subtotal parathyroidectomy was performed, leaving half of the left inferior parathyroid gland, and a prophylactic thymectomy was performed as well. In postsurgical histological tests, the diagnosis of parathyroid adenoma was confirmed (Fig. 6). After surgery, the intact-PTH level was decreased to 5.79 pg/mL. The remaining tumors are under follow up observation.

**DISCUSSION**

MEN1 can be diagnosed by the identification of two or more of the following: parathyroid tumor, pancreatic islet cell tumor, and pituitary adenoma. In addition, MEN1 may also include a carcinoid tumor, lipoma, adrenal gland tumor, adrenal
MEN1 is inherited autosomally dominantly in most cases, and occurs in familial or sporadic forms. In Korea, approximately 24 cases have been previously reported, and among them, 11 cases were familial, and cases with accompanying leiomyoma have not been reported. The clinicopathological features of MEN1-associated tumors are generally similar to those of tumors arising sporadically in the same tissue; nevertheless, MEN1-associated tumors show a distinct pattern in three aspects. Firstly, MEN1 develops in several endocrine tissues and is multicentric. Due to its multicentric characteristic, its recurrence rate after surgery is high. Secondly, some MEN1 tumors (parathyroid and gastrin cell) typically present approximately one or more decades earlier than sporadic tumors of the same tissue. Thirdly, some MEN1 tumors have the potential for malignancy, and the pertinent malignant tumors have been known to be a major cause of death in MEN1 patients. The parathyroid is the most prevalent endocrine organ affected, and parathyroid involvement is seen in 90% of patients. In Korea, a tumor in the parathyroid was seen in 83% of cases. In nine of these cases, pathological findings were reported in the literature, and 56% (5 cases) were parathyroid hyperplasia, and 44% (4 cases) were parathyroid adenoma (Table 1).

Pancreatic islet cells tumors are detected in approximately 30-80% of MEN1 cases, and these could be either functional or non-functional. In the cases of functional tumors, it has been reported that various hormones could be released. In Korean MEN1 cases, a pancreatic islet cell tumor was developed in 96% of the cases. Cases secreting insulin (32%, 8 cases) and gastrin (20%, 5 cases) were most prevalent among functional tumors. The cases considered to be non-functional were 16% (4 cases) (Table 1).

Pituitary tumors, most commonly prolactinomas, are present in 10-50% of symptomatic MEN1 patients. In Korean cases, a pituitary tumor was detected in 75% of the cases, and among them, prolactin-secreting adenoma was the most prevalent, making up 68% (13 cases) (Table 1).

Other so-called non-classical neoplasms occur

---

Fig. 5. Sequencing of exon 7 in the MEN1 gene shows a missense mutation (D350V).

Fig. 6. The parathyroid adenoma was composed of a single cell proliferation of enlarged chief cells without any fat cells present. The chief cells had clear to slightly eosinophilic cytoplasm and round to oval nuclei with heavy chromatin distribution. The cells are arranged in a glandular and solid pattern (Hematoxylin-eosin, ×200).
Table 1. Summary of 24 Cases of MEN1 in Koreans

| Case No. | Age (yrs) | Sex | Pituitary tumor | Parathyroid tumor | Pancreas tumor | Others | Gene analysis | Exon | Codon Mutation | Reference |
|----------|-----------|-----|------------------|-------------------|---------------|--------|--------------|------|----------------|-----------|
| 1        | 36        | F   | GH +             | hyperparathyroidism | hormone -      | adrenal gland tumor | (-)          |      |                | 5         |
| 2        | 41        | F   | ()              | adenoma           | gastrin +     | adrenal adenoma, Rt | (-)          |      |                | 6         |
| 3        | 37        | M   | prolactin +     | hyperplasia       | glucagon +    | adrenal nodular hyperplasia, Lt | (-)          |      |                | 7         |
| 4        | 38        | M   | prolactin +     | hyperparathyroidism | (-)          | (-)          | (-)          |      |                | 7         |
| 5        | 51        | F   | GH+             | hyperparathyroidism | insulin +, gastrin + | stomach carcinoid | (-)          |      |                | 7         |
| 6        | 35        | M   | prolactin +     | (-)              | non-function | adrenal adenoma, Rt | (-)          |      |                | 7         |
| 7        | 38        | F   | prolactin +     | (-)              | insulin +    | adrenal adenoma, Lt. thyroid adenoma | (-)          |      |                | 8         |
| 8        | 36        | F   | prolactin +     | hyperplasia       | insulin +    | (-)          | (-)          |      |                | 9         |
| 9        | 49        | M   | ()              | hyperplasia       | VIP+pancreatic polypeptide + | (-)          | (-)          |      |                | 10        |
| 10       | 45        | M   | prolactin +     | (-)              | gastrin +    | (-)          | (-)          |      |                | 11        |
| 11       | 47        | F   | ()              | hyperplasia       | gastrin +    | (-)          | (-)          |      |                | 12        |
| 12       | 45        | M   | GH+, prolactin + | hyperparathyroidism | gastrin +    | (-)          | (-)          |      |                | 13        |
| 13       | 42        | M   | prolactin +     | hyperplasia       | Non-function | thymic carcinoid, bilateral adrenal hyperplasia | (-)          |      |                | 14        |
| 14       | 22        | F   | prolactin +     | (-)              | insulin +    | (-)          | (+)          | 2    | 67 frameshift mutation 200-201insAGCCC | 15        |
| 15       | 70        | M   | ()              | adenoma           | VIP +        | (-)          | (+)          | 9    | 383 Point mutation GAC→CAT | 16        |
| 16       | 31        | F   | prolactin +     | (?)              | insulin +    | (-)          | (-)          |      |                | 17        |
| 17       | 31        | F   | non-function prolactin + | hyperparathyroidism | insulin +    | (-)          | (-)          |      |                | 17        |
| 18       |          |     | ()              | somatostatin +    | (-)          | (+)          | 9    | 405 nonsense mutation 1213C>T | 18        |
| 19       |          |     | non-function hyperparathyroidism | non-function | (-)          | (+)          | 2    | 67 frameshift mutation 210-211insAGCCC | 18        |
| 20       |          |     | prolactin +     | hyperparathyroidism | insulin +, glucagon + | (-)          | (+)          | 7    | 325 missense mutation 975G>C | 18        |
| 21       |          |     | prolactin +     | hyperparathyroidism | insulin +    | (-)          | (+)          | 7    | 325 nonsense mutation 969C>A | 18        |
| 22       |          |     | ()              | hyperparathyroidism | VIP +        | (-)          | (+)          |      | not detected | 18        |
| 23       | 50        | F   | non-function adenoma | non-function | leiomyoma    | (+)          | (+)          | 7    | 350 missense mutation 1159A>T | -         |
| 24       | 82        | F   | ()              | adenoma           | non-function | (-)          | (+)          | 7    | 350 missense mutation 1159A>T | -         |

Penetrance: 75% 83% 96% 67%

M, male; F, female.
frequently in MEN1 patients. Adrenal cortical tumors are detected in approximately 40% of Korean patients. The majority of these tumors were bilateral, hyperplastic and non-functional, and caused minimal morbidity. In addition to endocrine tumors, non-endocrine mesenchymal tumors, such as lipoma, angiofibroma, collagenoma, and leiomyoma, have been reported to be associated with MEN1 and mutations in the MEN1 gene.\(^2,19-21\) Leiomyoma has been reported to develop in the esophagus, lung, uterus, skin, and ureter, and the difference from sporadic leiomyoma is its multicentric development in many cases.\(^2,3\) In Korean reports, non-endocrine tumors have only been reported in three cases: carcinoid tumors (two cases) and leiomyomas (the current study).\(^5-8,14\)

The MEN1 gene is localized to chromosome 11q13, was identified by positional cloning, and is composed of 10 exons.\(^22,23\) It encodes a 610 amino acid protein, menin, which is localized primarily to the nucleus.\(^23\) Menin has a tumor-suppressor function that involves direct binding to the JunD protein and the inhibition of JunD-dependent transcription.\(^24\) Mutation sites in the MEN1 gene are found throughout the entire coding region. A genotype-phenotype correlation has not been clearly established for the mutations, although it has been suggested that some of the mutations might be associated with the formation of specific tumors.\(^25\)

In Korea, genetic analysis has been reported in only 38% of MEN1 patients. This analysis is summarized in Table 1, and a frameshift mutation was detected in two cases, a nonsense mutation in two cases, and a missense mutation in three cases. In our case, a germline missense mutation, D350V, was identified. To our knowledge, this mutation has not been reported to date.\(^18,26-30\)

The first DNA analysis of a leiomyoma of the esophagus in a patient with MEN1 failed to detect allelic deletions at the MEN1 locus.\(^19\) This implied that the tumor arose through a completely independent mechanism not associated with the patient's underlying MEN1 disease. However, in a study conducted subsequently, loss of heterozygosity (LOH) at the MEN1 locus was shown in two esophageal leiomyomas from a MEN1 patient.\(^20\) Meanwhile, another study reported that the MEN1 gene contributes to the development of multiple esophageal and uterine leiomyomas in MEN1 patients and that the gene does not play a significant role in the tumorigenesis of sporadic uterine leiomyoma.\(^2\) Thus, leiomyomas in MEN1 and sporadic patients most likely develop through different mechanisms.

In conclusion, although leiomyomas in MEN1 have not previously been reported in Korea, they should be considered an integral part of MEN1 and examined carefully. Additionally, we found a novel mutation, D350V, in exon 7 of the MEN1 gene.

REFERENCES

1. Doherty GM. Multiple endocrine neoplasia type 1. J Surg Oncol 2005;89:143-50.
2. McKeeby JL, Li X, Zhuang Z, Vortmeyer AO, Huang S, Pirner M, et al. Multiple leiomyomas of the esophagus, lung, and uterus in multiple endocrine neoplasia type 1. Am J Pathol 2001;159:1121-7.
3. Ikota H, Tanimoto A, Komatsu H, Ozawa Y, Matsushita H. Ureteral leiomyoma causing hydronephrosis in Type 1 multiple endocrine neoplasia. Pathol Int 2004;54:457-9.
4. Schusseheim DH, Skarulis MC, Agarwal SK, Simonds WF, Burns AL, Spiegel AM, et al. Multiple endocrine neoplasia type 1: new clinical and basic findings. Trends Endocrinol Metab 2001;12:173-8.
5. Oh KY, Lee NS, Jang DS, You KH, Baek HS. Multiple Endocrine Neoplasm Type 1: A Case Report. Korean J Intern Med 1986;31:229-35.
6. Chun SW, Moon IS, Kim JG, Park WB, Chun JS, Park WS, et al. Multiple Endocrine Neoplasm, Type I. J Korean Surg Soc 1991;40:684-90.
7. Kim HK, Kim CH, Park JY, Shong YK, Lee KU, Kim GS. Clinical Features of Multiple Endocrine Neoplasia type 1 in Koreans. J Korean Soc Endocrinol 1996;11:163-74.
8. Yoo SJ, Cha BY, Lee KW, Son HY, Kang SK, Won JM, et al. A case of multiple endocrine neoplasia type 1. J Korean Soc Endocrinol 1997;12:1119.
9. Hong SB, Hong SJ, Song YK, Kim KS, Kim SW, Lee KU, et al. A case of multiple endocrine neoplasia type I presented with secondary amenorrhea and osteoporosis. J Korean Soc Endocrinol 1998;13:684-9.
10. Choe WH, Park YJ, Hong IC, Park SH, Choi SC, Lee HR, et al. A case of multiple endocrine type I presenting with a watery diarrhea. J Korean Soc Endocrinol 2001;16:231-7.
11. Lee SK, Lee KW, Kim HJ, Lee SH, Yoon JG, Han SW, et al. Zollinger-Ellison Syndrome Associated with Multiple Endocrine Neoplasia Ia. Korean J Gastrointest
12. Lee YM, Jung HY, Choi SY, Kang HH, Myung SJ, Yang SK, et al. A case of metachronous multiple endocrine neoplasia type I manifested as Zollinger-Ellison syndrome. Korean J Gastroenterol 2002;39:50-4.

13. Kim JH, Lee KU, Kim WH, Kim YI. Multiple Pancreatic islet cell tumors with diverse hormonal expression in a multiple endocrine neoplasia type I patient: a case report. Korean J Pathol 2002;36:184-6.

14. Cho MH, Lee KM, Song DH, Ahn CW, Kim KR, Hwang JJ, et al. A case of multiple endocrine neoplasia type I with thymic carcinoid tumor. Korean J Intern Med 2005;20:428-33.

15. Park SE, Kang ES, Lee HJ, Kim SH, Do MY, Kang SA, et al. A case of multiple endocrine neoplasia type 1 with mutation in MENIN gene. J Korean Soc Endocrinol 2005;20:71-7.

16. Lee SW, Choi YS, Park YH, Oh KS, Shin JW, Kim JJ, et al. A case of multiple endocrine neoplasia associated with VIPoma. J Korean Soc Endocrinol 2005;20:64-70.

17. Park DH, Kang DG, Kim SC, Sohn KR. Familial multiple endocrine neoplasia, type I, in identical twins. J Korean Neurosurg Soc 2003;34:369-71.

18. Park JH, Kim IJ, Kang HC, Lee SH, Shin Y, Kim KH, et al. Germline mutations of the MEN1 gene in Korean families with multiple endocrine neoplasia type 1 (MEN1) or MEN1-related disorders. Clin Genet 2003;64:48-53.

19. Dong Q, Debeelenko LV, Chandrasekharappa SC, Emmert-Buck MR, Zhuang Z, Guru SC, et al. Loss of heterozygosity at 11q13: analysis of pituitary tumors, lung carcinoids, lipomas, and other uncommon tumors in subjects with familial multiple endocrine neoplasia type 1 (MEN1) or MEN1-related disorders. Clin Genet 2003;64:48-53.

20. Vortmeyer AO, Lubensky IA, Skarulis MC, Wu YM, Park WS, et al. Multiple endocrine neoplasia type 1: atypical presentation, clinical course, and genetic analysis of multiple tumors. Mod Pathol 1999;12:919-24.

21. Pack S, Turner ML, Zhuang Z, Vortmeyer AO, Böni R, Skarulis M, et al. Cutaneous tumors in patients with multiple endocrine neoplasia type 1 show allelic depletion of the MEN1 gene. J Invest Dermatol 1998;110:438-40.

22. Larsson C, Skogseid B, Oberg K, Nakamura Y, Nordenskjöld M. Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma. Nature 1988;332:85-7.

23. Chandrasekharappa SC, Guru SC, Manickam P, Olufermi SE, Collins FS, Emmert-Buck MR, et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 1997;276:404-7.

24. Agarwal SK, Guru SC, Heppner C, Erdos MR, Collins RM, Park SY, et al. Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription. Cell 1999;96:143-52.

25. Kouvaraki MA, Lee JE, Shapiro SE, Gagel RF, Sherman SI, Sellin RV, et al. Genotype-phenotype analysis in multiple endocrine neoplasia type 1. Arch Surg 2002;137:641-7.

26. Guo SS, Sawicki MP. Molecular and genetic mechanisms of tumorigenesis in multiple endocrine neoplasia type-1. Mol Endocrinol 2001;15:1653-64.

27. Agarwal SK, Kester MB, Debeelenko LV, Heppner C, Emmert-Buck MR, Skarulis MC, et al. Germline mutations of the MEN1 gene in familial multiple endocrine neoplasia type 1 and related states. Hum Mol Genet 1997;6:1169-75.

28. Wautot V, Vercherat C, Lespinasse J, Chambe B, Lenoir GM, Zhang CX, et al. Germline mutation profile of MEN1 in multiple endocrine neoplasia type 1. Mol Endocrinol 2001;15:1165-64.

29. Mutch MG, Dilley WG, Sanjurjo F, DeBenedetti MK, Doberty GM, Wells SA Jr, et al. Germline mutations in the MEN1 gene in familial multiple endocrine neoplasia type 1 and related conditions. Hum Mol Genet 1999;8:1169-75.

30. Roijers JF, de Wit MJ, van der Luit RB, Ploos van Amstel HK, Hoppener JW, Lips CJ. Criteria for mutation analysis in MEN 1-suspected patients: MEN 1 case-finding. Eur J Clin Invest 2000;30:487-92.